MISGAV, Israel, June 4, 2012 /PRNewswire/ —

MitrAssist Medical Ltd., a developer of minimally invasive products for treating heart disease, announced today that it received ISO 13485:2003 Certification for the design and development of implantable heart valve prostheses.

Today’s standard treatment for mitral valve regurgitation (MR), blood leakage or backflow into the atrium, is open heart surgery. MitrAssist’s unique design preserves the ventricular dynamic mode of function and mechanism, known to be crucial for long term patient outcome. MitrAssist’s mitral valve prosthesis is delivered with a minimally invasive procedure via a small-diameter catheter, keeping the existing valve intact. With its unique design focused on natural mitral valve anatomy, the MitrAssist mitral valve prosthesis will enable faster transition to minimally invasive procedures for mitral repair.

“This is yet another small step for us moving forward towards developing a viable and effective solution to Mitral Valve Insufficiency, following our successful completion of the chronic animal study POC,” said Gil Naor, MitrAssist founder and CEO.

About MitrAssist Ltd.

MitrAssist Ltd. was founded in 2009 by Gil Naor, a recognized innovator in developing medical devices, including a number of devices for cardiology. The company is a portfolio company of The Trendlines Group’s Misgav Venture Accelerator. MitrAssist Ltd. develops minimally invasive products for treating heart valve disease. The Company’s first product is a percutaneous mitral valve prosthesis for treatment of MR.

About Trendlines

The Trendlines Group (http://www.trendlines.com) establishes, invests in, and develops innovation-based businesses in the medical and agritech fields. Seed-stage investors, Trendlines invests principally through a platform of Israeli government-licensed business accelerators, Misgav Venture Accelerator (http://www.misgav-venture.com) and Mofet Venture Accelerator (http://www.mofet-venture.com). Over the last four years, Trendlines has attracted investments exceeding 140 million$.

Media relations:
Dorit Orly +972-52-2525167
Ofir Shpigel’s Media and Public Relations
+972-4-9535030

SOURCE MitrAssist Medical Ltd